Related Experiment Videos

Author's reply to: The real-world outcome of metastatic melanoma: Unknown primary vs. known cutaneous

Danielle Verver¹, Astrid A M van der Veldt², Alexander C J van Akkooi³

¹Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

International Journal of Cancer

|August 20, 2019

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Impact of adjuvant therapy on melanoma-specific survival in elderly patients with high-risk resected melanoma: a multicenter international retrospective study.

Journal for immunotherapy of cancer·2026

Global disparities in the availability and reimbursement of systemic therapies for renal cell carcinoma: results of the International ARON-AID Survey.

The oncologist·2026

Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).

Nature medicine·2026

Early Cessation of Adjuvant Anti-PD-1 Therapy in Stage III and IV Melanoma.

International journal of cancer·2026

Neutralizing the IL-12/IL-23 p40 subunit prevents immune checkpoint blockade toxicity without compromising antitumor efficacy.

Cancer immunology research·2026

Adjuvant Systemic Therapy in Melanoma: Relative versus absolute benefit; the number needed to treat (NNT) versus the number needed to harm (NNH)?

EJC skin cancer·2026

See all related articles